オプションチェーンは、CERo Therapeutics Hldgsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、CERo Therapeutics Hldgsの市場センチメントを評価します。.

CERo Therapeutics Hldgs (NASDAQ:CERO) 株価情報, オプションチェーン

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

Zai Lab Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares are trading higher by 3.45% to $27.59 during Friday&#8217;s session. The company priced a $200 million public offering of 7,843,137 shares at <a href="https://www.benzinga.com/pressreleases/24/11/b41997659/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares">$25.50 per ADS</a>.
The offering is expected to close on November 18, subject to customary conditions. The company has also granted underwriters a 30-day option to purchase an additional 1,176,470 ADSs. 
Net proceeds will be used for general corporate purposes. Goldman Sachs, Jefferies and Leerink Partners are the joint book-running managers for the offering.
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a>
<h2 class="wp-block-heading">How To Buy ZLAB Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instruments.
For example, in Zai Lab&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ZLAB has a 52-week high of $36.50 and a 52-week low of $13.48.

News

ZLAB

Why Zai Lab (ZLAB) Stock Is Trading Higher

Raymond James analyst Stephen Boland maintains Pollard Banknote (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBL#TSX">PBL</a>) with a Outperform and raises the price target from C$44 to C$46.

Price Target

Analyst Ratings

TSX:PBL

Raymond James Maintains Outperform on Pollard Banknote, Raises Price Target to C$46

AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are moving lower on Friday after the company reported worse-than-expected 2024 third-quarter fiscal earnings after the bell <a href="https://www.benzinga.com//node/41994523">on Thursday</a>.
What Happened: AST SpaceMobile shares fell about 13% after the company released earnings on Thursday. The earnings report included a loss of $1.10 per share, missing analyst estimates of a loss of 20 cents per share.
Furthermore, the company reported sales of $1.10 million, missing analyst estimates of $24.13 million. AST SpaceMobile reported other key pieces of financial data, including adjusted operating expenses of $45.3 million.
The company incurred about $374 million of gross capitalized property and equipment costs. It also reported $518.9 million in cash, cash equivalents and restricted cash. 
Stepping back from finances, the company announced several key agreements, such as launch service agreements with Blue Origin for launches in 2025 and 2026. These agreements will enable the orbital deployment of up to 60 Block 2 BlueBird satellites.
The company&#8217;s coverage will initially target key markets, including the U.S., Japan, and Europe.
Additionally, the company achieved initial validation of its AST5000 ASIC chip, with the necessary infrastructure in place for commissioning in 2025. The combination of the new chip and the larger Block 2 array will support enhanced data transmission.
&#8220;We achieved many significant milestones in the quarter and continue our momentum with several key pieces now in place,&#8221; said Abel Avellan, founder, chairman and CEO of AST SpaceMobile. 
&#8220;With the first five BlueBird satellites successfully unfolded and entering initial operations, our business is progressing according to plan. We&#8217;ve advanced our strategy across multiple efforts including progress on securing orbital launch capacity, growing our manufacturing capability, and expanding our customer ecosystem.&#8221;
Following the earnings report, UBS analyst Christopher Schoell maintained a Buy rating on AST SpaceMobile and raised the price target from&nbsp;$30&nbsp;to&nbsp;$31.
Related Link: <a href="https://www.benzinga.com/24/11/41961161/musk-ramaswamy-headed-doge-department-will-be-an-incredibly-challenging-endeavor-says-ted-cruzshares-this-piece-o">Ted Cruz Says Running DOGE Won&#8217;t Be A Cake Walk, Offers Reading Advice To Elon Musk</a>
ASTS Price Action: At the time of publication, AST SpaceMobile shares are moving 13.8% lower at $23.11, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Company

Movers

ASTS

What's Going On With AST SpaceMobile Stock Friday?

Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) stock is moving lower Friday after Warren Buffet&#8216;s Berkshire Hathaway <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">cut its position in the company. </a>
What To Know: Buffet&#8217;s Berkshire Hathaway cut nearly all of its position in the beauty brand, according to Berkshire&#8217;s latest 13F filing.
Berkshire initially reported holding 690,106 shares in Ulta in an August filing. The latest 13F filing, released Thursday, shows its position has been reduced to 24,203 shares, a 96% cut.
The filing also indicates new positions in Domino&#8217;s Pizza Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) and Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>). Berkshire acquired 1,277,256 shares of Domino&#8217;s, valued at approximately $549 million, and 404,057 shares of Pool Corp, worth about $152 million.
Furthermore, the filing shows that Berkshire continued to reduce its stake in Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>). The August filing represents the company&#8217;s holdings as of June 30, while Thursday&#8217;s filing reports Berkshire&#8217;s holdings as of Sept. 30.
How To Buy Ulta Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Ulta Beauty's case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a>
ULTA Price Action: At the time of writing, Ulta stock is moving 2.39% lower at $373.24, Domino&#8217;s shares are moving 2.07% higher at $444.98, Pool stock is moving 2.52% higher at $366.51, Bank of America shares are trading 0.86% higher at $46.29, and Apple stock is moving 1.45% lower at $244.88 per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Wikimedia Commons

AAPL

POOL

ULTA

What's Going On With Ulta Beauty Shares Friday?

Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Friday.</a>
The company reported fourth-quarter adjusted earnings per share of 97 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42004018/spectrum-brands-holdings-reports-fiscal-2024-fourth-quarter" rel="noreferrer noopener">missing the street view of $1.07</a>. Quarterly revenues were $773.7 million (+4.5%), beating the analyst consensus of $747.51 million.
Gross profit surged 17.8% to $288 million. Gross profit and margin increased due to productivity improvements, operational efficiencies, and inventory actions in the prior year, partially offset by ocean freight inflation.
Adjusted EBITDA decreased $42.6 million, driven by $32.5 million of lower investment income and $25.9 million of increased brand-focused investments, offset by gross profit improvements.
As of the fiscal year-end, the company reported a cash balance of $369 million and total liquidity of $860 million, including undrawn capacity on its cash flow revolver.
It had $578 million in outstanding debt, consisting of $496 million in senior unsecured notes and around $82 million in finance lease obligations, resulting in a net debt of approximately $209 million.
Outlook: Spectrum Brands expects low single-digit growth in reported net sales in fiscal 2025 and adjusted EBITDA to increase by mid to high single-digits. Adjusted free cash flow is expected to be approximately<a href="https://www.benzinga.com/calendars/guidance"> 50% of adjusted EBITDA.</a>
The company continues to target a long-term net leverage ratio of 2.0 &#8211; 2.5 times.
&#8220;I am excited about the upcoming year. Our focus during fiscal 2025 will be to continue the momentum we built in fiscal 2024 by investing in our brands to drive long-term growth, in innovation to expand core and adjacent categories, and in our operations to drive further cost improvement, quality and safety,&#8221; said David Maura, Chairman and Chief Executive Officer of Spectrum Brands.
Price Action: SPB shares are trading lower by 4.78% to $89.38&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012197/totalenergies-joins-bp-equinor-and-shell-in-500m-drive-for-global-energy-access\" target="_blank" rel="noreferrer noopener">TotalEnergies Joins BP, Equinor, And Shell In $500M Drive For Global Energy Access</a></li>
</ul>

Earnings

Equities

Guidance

Markets

General

Spectrum Brands Stock Falls After Q4 Earnings Miss On Lower Investment Income: Details

Raymond James analyst Michael Barth reiterates Enerflex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EFX#TSX">EFX</a>) with a Outperform and raises the price target from C$12 to C$13.75.

Reiteration

TSX:EFX

Raymond James Reiterates Outperform on Enerflex, Raises Price Target to C$13.75

RBC Capital analyst Matthew McKellar reiterates Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Outperform and maintains $58 price target.

RBC Capital Reiterates Outperform on Smurfit WestRock, Maintains $58 Price Target

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.&#8217;s nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.
Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.
Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.
Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.
In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;
On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.
European vaccine player stocks declined, including&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.
COVID-19 vaccine players <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.
Other vaccine players&#8217; stocks that are down include Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Inovio Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).
Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Biotech

Large Cap

Eurozone

Health Care

Trading Ideas

BNTX

MRNA

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

WIIM

NDRA

ENDRA Life Sciences shares are trading lower. The company reported Q3 financial results.

Raymond James analyst Stephen Boland maintains CI Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CIX#TSX">CIX</a>) with a Outperform and raises the price target from C$22 to C$27.

TSX:CIX

Raymond James Maintains Outperform on CI Financial, Raises Price Target to C$27

ALRN

Aileron Therapeutics shares are trading lower. The company reported Q3 financial results.

RBC Capital analyst Jimmy Shan maintains Flagship Communities (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MHC#TSX">MHC</a>) with a Outperform and raises the price target from C$19 to C$20.

TSX:MHC

TSX:MHC/U

RBC Capital Maintains Outperform on Flagship Communities, Raises Price Target to C$20

OMGA

Omega Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results and Piper Sandler cut its price target on the stock from $9 to $4.

ALUR

Allurion Technologies shares are trading lower after Chardan Capital downgraded the stock from Buy to Neutral.

BMO Capital analyst Ben Pham maintains Boralex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLX#TSX">BLX</a>) with a Outperform and lowers the price target from C$46 to C$45.

TSX:BLX

BMO Capital Maintains Outperform on Boralex, Lowers Price Target to C$45

VUZI

Vuzix shares are trading lower after the company reported worse-than-expected Q3 financial results.

Deep-pocketed investors have adopted a bearish approach towards Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TEM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Tempus AI. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 50% bearish. Among these notable options, 6 are puts, totaling $683,586, and 2 are calls, amounting to $99,000.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $55.0 for Tempus AI during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Tempus AI's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tempus AI's whale activity within a strike price range from $30.0 to $55.0 in the last 30 days. 
<h3>Tempus AI 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731687434_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.8</td>
<td>$4.5</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$246.2K</td>
<td align="right">85</td>
<td align="right">500</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.3</td>
<td>$5.0</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$225.7K</td>
<td align="right">85</td>
<td align="right">462</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.7</td>
<td>$4.3</td>
<td>$4.7</td>
<td>$52.00</td>
<td>$92.5K</td>
<td align="right">206</td>
<td align="right">200</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$9.2</td>
<td>$7.7</td>
<td>$9.2</td>
<td>$55.00</td>
<td>$63.4K</td>
<td align="right">10</td>
<td align="right">90</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$23.7</td>
<td>$22.0</td>
<td>$23.0</td>
<td>$30.00</td>
<td>$50.6K</td>
<td align="right">0</td>
<td align="right">44</td>
</tr>
</tbody>
</table>

<h3>About Tempus AI</h3>
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
After a thorough review of the options trading surrounding Tempus AI, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Tempus AI</h3>
<ul>
<li>With a trading volume of 572,433, the price of TEM is up by 0.32%, reaching $56.81.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 94 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Tempus AI</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $67.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $70. 
&#x2A; Reflecting concerns, an analyst from Stifel lowers its rating to Hold with a new price target of $65.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Tempus AI with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Behind the Scenes of Tempus AI's Latest Options Trends

Deep-pocketed investors have adopted a bearish approach towards Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TTD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Trade Desk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 19% leaning bullish and 71% bearish. Among these notable options, 11 are puts, totaling $1,047,442, and 10 are calls, amounting to $2,142,826.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $140.0 for Trade Desk during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Trade Desk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Trade Desk's significant trades, within a strike price range of $90.0 to $140.0, over the past month.
<h3>Trade Desk Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731687428_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$34.85</td>
<td>$34.25</td>
<td>$34.4</td>
<td>$90.00</td>
<td>$1.0M</td>
<td align="right">746</td>
<td align="right">301</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.5</td>
<td>$9.45</td>
<td>$9.45</td>
<td>$105.00</td>
<td>$608.5K</td>
<td align="right">16</td>
<td align="right">644</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$32.2</td>
<td>$32.0</td>
<td>$32.0</td>
<td>$92.50</td>
<td>$320.0K</td>
<td align="right">634</td>
<td align="right">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$32.8</td>
<td>$31.05</td>
<td>$32.4</td>
<td>$92.50</td>
<td>$181.4K</td>
<td align="right">634</td>
<td align="right">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.2</td>
<td>$26.75</td>
<td>$27.09</td>
<td>$115.00</td>
<td>$162.8K</td>
<td align="right">486</td>
<td align="right">60</td>
</tr>
</tbody>
</table>

<h3>About Trade Desk</h3>
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>With a volume of 1,511,116, the price of TTD is down -1.1% at $124.49. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Trade Desk</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $109.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Trade Desk with a target price of $135. 
&#x2A; An analyst from DA Davidson persists with their Buy rating on Trade Desk, maintaining a target price of $134. 
&#x2A; An analyst from New Street Research has revised its rating downward to Sell, adjusting the price target to $86. 
&#x2A; An analyst from Benchmark downgraded its action to Sell with a price target of $57. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Trade Desk with a target price of $135. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Trade Desk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Unpacking the Latest Options Trading Trends in Trade Desk

Investors with a lot of money to spend have taken a bearish stance on Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NKE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 25 uncommon options trades for Nike.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 52%, bearish.
Out of all of the special options we uncovered, 16 are puts, for a total amount of $888,906, and 9 are calls, for a total amount of $375,233.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $95.0 for Nike, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Nike's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Nike's significant trades, within a strike price range of $60.0 to $95.0, over the past month.
<h3>Nike Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731687423_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.59</td>
<td>$2.53</td>
<td>$2.53</td>
<td>$75.00</td>
<td>$126.5K</td>
<td>16.5K</td>
<td>526</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.53</td>
<td>$2.46</td>
<td>$2.51</td>
<td>$75.00</td>
<td>$125.2K</td>
<td>16.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.35</td>
<td>$3.25</td>
<td>$3.35</td>
<td>$95.00</td>
<td>$82.7K</td>
<td>1.8K</td>
<td>1</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.1</td>
<td>$80.00</td>
<td>$67.7K</td>
<td>12.0K</td>
<td>222</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.08</td>
<td>$80.00</td>
<td>$67.0K</td>
<td>12.0K</td>
<td>111</td>
</tr>
</tbody>
</table>

<h3>About Nike</h3>
Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
Following our analysis of the options activities associated with Nike, we pivot to a closer look at the company's own performance.
<h3>Where Is Nike Standing Right Now?</h3>
<ul>
<li>With a volume of 3,359,657, the price of NKE is up 0.86% at $76.33. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 34 days.</li>
</ul>
<h3>What Analysts Are Saying About Nike</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $80.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Nike with a target price of $80. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Nike, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Nike's Latest Options Trends

Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) stock has climbed following Donald Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election win</a>, driven by expectations of economic policies that could stimulate consumer spending and benefit payment processors like Visa.
Trump's proposal to extend and expand tax cuts is likely to increase disposable income for households and encourage corporate investment, leading to a surge in transaction volumes—Visa's primary revenue source.
What Else: Additionally, Trump's deregulatory agenda could benefit Visa by reducing compliance costs in the financial sector, allowing the company to invest more aggressively in innovation. 
This could accelerate Visa's development of digital payment technologies, enhance its global network, and foster partnerships with emerging fintech companies. Visa is well-positioned to capitalize on this growth as digital transactions continue to replace cash worldwide.
Trump's focus on economic expansion through infrastructure spending and trade reforms could further bolster Visa's business segment by increasing corporate transactions and cross-border payment activity. 
Potential inflationary pressures under Trump's policies may also indirectly benefit Visa, as higher transaction values generate increased processing fees.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/42006281/alibaba-q2-earnings-revenue-beats-forecast-cloud-and-international-sales-shine-free-cash-flow-falls-amid-strategic-investments">Alibaba Q2 Earnings: Revenue Beats Forecast, Cloud and International Sales Shine, Free Cash Flow Falls Amid Strategic Investments</a>
<h2 class="wp-block-heading">Is V A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/V">Visa</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Visa does pay a dividend, which yields 0.78% per year as of the closing price on Nov. 15, 2024. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/V">Visa</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, V has a 52-week high of $312.44 and a 52-week low of $245.60.

Why Visa Stock Hit A New 52-Week High This Week

CERo Therapeutics Holdings ( ($CERO) ) has issued an update. CERo Therapeutics Holdings, Inc. has secured $1.25 million through a private placement...

CERo Therapeutics' Strategic Moves Amidst Leadership Change

CERo Therapeutics Holdings ( ($CERO) ) has shared an update. CERo Therapeutics Holdings, Inc. has strategically bolstered its leadership with the a...

CERo Therapeutics Enhances Leadership for Clinical Advancements

CERo Therapeutics gets new finance head

CERo Therapeutics Holdings ( ($CERO) ) has issued an update. Shami Patel, a seasoned financial expert with over 25 years of experience, has been ap...

CERo Therapeutics Welcomes Shami Patel to Board After Resignation

CERo Therapeutics (CERO) provides the following corporate update to stockholders from Interim CEO Chris Ehrlich, "Following the events of the last ...

Cero Therapeutics submits IND clinical hold CRL to the FDA

16:44 EDT Cero Therapeutics (CERO) files to sell 713.56M shares of common stock for holders Published first on TheFly – the ultimate source for rea...

Cero Therapeutics files to sell 713.56M shares of common stock for holders

CERo Therapeutics files to sell 713.6M shares of common stock for holders

CERo Therapeutics stock is rising higher on Monday as investors react to the latest preclinical data concerning lead compound CER-1236.

CERo Therapeutics' (CERO) Stock Sees Significant Climb After Revealing Ovarian Cancer Data

FOXO Technologies, CERo Therapeutics Holdings, and Mullen Automotive are the 3&nbsp;Penny Stocks&nbsp;to watch on November 14, 2024, based on&nbsp;...

3 Penny Stocks to Watch Now, 11/24/24

CERo Therapeutics (CERO) announces that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug Application for Ph...

Cero Therapeutics receives FDA clearance of IND application for CER-1236

CERO

FOXO

MULN

Press Releases

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

GlycoMimetics

HOOKIPA Pharma

ImmuCell

IN8bio

MiNK Therapeutics

Kairos Pharma

Longeveron

Marker Therapeutics

Ocean Biomedical

Pluri

RenovoRx

SAB Biotherapeutics

Surrozen

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

CERo Therapeutics shares are trading higher after the company received FDA clearance for its investigational new drug application to initiate a Phase 1 clinical trial of CER-1236 for acute myelogenous leukemia.

Comments

CERo Therapeutics Hldgs

CERo Therapeutics Hldgs (CERO) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル